Toripalimab (240mg day1, Q3W*3cycle)
Sponsors
Nanfang Hospital, Southern Medical University, Tianjin Medical University Cancer Institute and Hospital
Conditions
Locally Advanced Esophageal Squamous Cell CarcinomaNSCLC
Phase 2
A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
RecruitingNCT06843889
Start: 2025-04-03End: 2028-08-01Target: 34Updated: 2025-04-16
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
Not yet recruitingNCT07358689
Start: 2026-01-30End: 2029-01-01Target: 120Updated: 2026-01-22